JP6833851B2 - 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット - Google Patents

組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット Download PDF

Info

Publication number
JP6833851B2
JP6833851B2 JP2018530834A JP2018530834A JP6833851B2 JP 6833851 B2 JP6833851 B2 JP 6833851B2 JP 2018530834 A JP2018530834 A JP 2018530834A JP 2018530834 A JP2018530834 A JP 2018530834A JP 6833851 B2 JP6833851 B2 JP 6833851B2
Authority
JP
Japan
Prior art keywords
tag
antibody
cd38ecd
seq
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018530834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527533A (ja
Inventor
エー．ホール ジョン
エー．ホール ジョン
シュビン ペーター
シュビン ペーター
ベリー ジョディー
ベリー ジョディー
ファバロロ ビンチェンツォ
ファバロロ ビンチェンツォ
ブース エリザベス
ブース エリザベス
ビンダ マッテオ
ビンダ マッテオ
Original Assignee
グリフォルズ ダイアグノスティック ソリューションズ インコーポレイティド
グリフォルズ ダイアグノスティック ソリューションズ インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリフォルズ ダイアグノスティック ソリューションズ インコーポレイティド, グリフォルズ ダイアグノスティック ソリューションズ インコーポレイティド filed Critical グリフォルズ ダイアグノスティック ソリューションズ インコーポレイティド
Publication of JP2019527533A publication Critical patent/JP2019527533A/ja
Application granted granted Critical
Publication of JP6833851B2 publication Critical patent/JP6833851B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018530834A 2017-08-10 2018-06-01 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット Active JP6833851B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762543788P 2017-08-10 2017-08-10
US62/543,788 2017-08-10
PCT/IB2018/053939 WO2019030581A1 (en) 2017-08-10 2018-06-01 COMPOSITIONS, METHODS AND / OR KITS COMPRISING AN EXTRACELLULAR DOMAIN OF RECOMBINANT HUMAN CD38

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021015874A Division JP7289328B2 (ja) 2017-08-10 2021-02-03 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット

Publications (2)

Publication Number Publication Date
JP2019527533A JP2019527533A (ja) 2019-10-03
JP6833851B2 true JP6833851B2 (ja) 2021-02-24

Family

ID=62846219

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018530834A Active JP6833851B2 (ja) 2017-08-10 2018-06-01 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット
JP2021015874A Active JP7289328B2 (ja) 2017-08-10 2021-02-03 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット
JP2023012758A Pending JP2023041802A (ja) 2017-08-10 2023-01-31 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021015874A Active JP7289328B2 (ja) 2017-08-10 2021-02-03 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット
JP2023012758A Pending JP2023041802A (ja) 2017-08-10 2023-01-31 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット

Country Status (18)

Country Link
US (3) US11708418B2 (https=)
EP (3) EP3587445B1 (https=)
JP (3) JP6833851B2 (https=)
KR (2) KR102631281B1 (https=)
CN (2) CN117820498A (https=)
AR (1) AR112357A1 (https=)
AU (2) AU2018313028B2 (https=)
BR (1) BR112020002636A2 (https=)
CA (1) CA3070789A1 (https=)
EA (1) EA202090265A1 (https=)
ES (2) ES2911243T3 (https=)
HU (1) HUE065510T2 (https=)
MX (3) MX2020001489A (https=)
PL (1) PL3587445T3 (https=)
PT (1) PT3587445T (https=)
TW (1) TW201910349A (https=)
UY (1) UY37757A (https=)
WO (1) WO2019030581A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065510T2 (hu) * 2017-08-10 2024-05-28 Grifols Diagnostic Solutions Inc Immunglobulin Fc-régiót és poli-His domént tartalmazó oligomerizációs címke
US11746140B2 (en) * 2018-02-20 2023-09-05 F. Hoffman-La Roche Ag Composition comprising recombinant GPlbα receptor protein
CN112048019B (zh) * 2019-06-06 2023-05-09 鲁南制药集团股份有限公司 抗人cd47单克隆抗体
CN116635420A (zh) * 2020-09-10 2023-08-22 英创远达制药公司 血液筛查方法
KR20230066404A (ko) 2020-09-10 2023-05-15 카시 파마슈티컬스, 인코포레이티드 혈액 스크리닝 방법
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN114917413B (zh) * 2022-06-14 2023-04-28 健诺维(成都)生物科技有限公司 一种负载重组多肽的羊膜及其制备方法
WO2024172419A1 (ko) * 2023-02-16 2024-08-22 주식회사 디엔티 Cd38 또는 이의 단편을 포함하는 자가면역질환 치료용 조성물
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6506551B1 (en) * 1999-10-08 2003-01-14 North Shore - Long Island Jewish Research Institute CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
AU2001273121A1 (en) * 2000-06-30 2002-01-14 Pharmacia And Upjohn Company Recombinant staphylococcus aureus peptide deformylase
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
WO2008037257A2 (en) * 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL2185589T3 (pl) * 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
EP2573112A1 (en) * 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
WO2010083253A2 (en) * 2009-01-14 2010-07-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
HUE030100T2 (en) * 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
US20130029358A1 (en) * 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
AU2011295715B9 (en) * 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
KR102100388B1 (ko) * 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
US9926373B2 (en) * 2012-04-27 2018-03-27 Novo Nordisk A/S Human CD30 ligand antigen binding proteins
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9447193B2 (en) * 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
WO2015191546A2 (en) * 2014-06-10 2015-12-17 The Board Of Regents Of The University Of Texas System Adp-ribose detection reagents
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
EP3221358B1 (en) * 2014-11-18 2021-07-21 Janssen Pharmaceutica, N.V. Cd47 antibodies, methods, and uses
JP6649941B2 (ja) * 2015-02-16 2020-02-19 株式会社ファーマフーズ Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
US9944679B2 (en) * 2015-03-16 2018-04-17 The Catholic University Of America Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
PE20171790A1 (es) * 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
WO2017043466A1 (ja) * 2015-09-08 2017-03-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ＥｐｈＡ４抗体
AU2016352676A1 (en) * 2015-11-10 2018-05-31 University Medical Center Hamburg - Eppendorf ANTIGEN-binding polypeptides directed against CD38
HUE065510T2 (hu) * 2017-08-10 2024-05-28 Grifols Diagnostic Solutions Inc Immunglobulin Fc-régiót és poli-His domént tartalmazó oligomerizációs címke

Also Published As

Publication number Publication date
JP7289328B2 (ja) 2023-06-09
CN109790210B (zh) 2024-03-26
EP3464343A1 (en) 2019-04-10
JP2021088567A (ja) 2021-06-10
JP2019527533A (ja) 2019-10-03
MX2024008109A (es) 2024-07-19
CA3070789A1 (en) 2019-02-14
AR112357A1 (es) 2019-10-23
US11708418B2 (en) 2023-07-25
KR20240015159A (ko) 2024-02-02
JP2023041802A (ja) 2023-03-24
TW201910349A (zh) 2019-03-16
MX2024005669A (es) 2024-05-30
CN117820498A (zh) 2024-04-05
US20240132616A1 (en) 2024-04-25
EP4296680A2 (en) 2023-12-27
EP4296680A3 (en) 2024-03-20
EP3587445A1 (en) 2020-01-01
BR112020002636A2 (pt) 2020-07-28
EA202090265A1 (ru) 2020-06-05
AU2023204121B2 (en) 2026-04-23
PL3587445T3 (pl) 2024-04-29
HUE065510T2 (hu) 2024-05-28
AU2018313028B2 (en) 2023-05-25
AU2023204121A1 (en) 2023-07-20
ES2911243T3 (es) 2022-05-18
PT3587445T (pt) 2024-03-14
EP3464343B1 (en) 2022-03-23
ES2973864T3 (es) 2024-06-24
CN109790210A (zh) 2019-05-21
KR20200035194A (ko) 2020-04-02
WO2019030581A1 (en) 2019-02-14
MX2020001489A (es) 2020-03-20
EP3587445B1 (en) 2023-12-13
UY37757A (es) 2018-11-30
US20240092929A1 (en) 2024-03-21
US20210198376A1 (en) 2021-07-01
KR102631281B1 (ko) 2024-01-30
AU2018313028A1 (en) 2020-02-20
US20240228651A9 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
JP6833851B2 (ja) 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット
Kruljec et al. Alternative affinity ligands for immunoglobulins
Yang et al. Binding site on human immunoglobulin G for the affinity ligand HWRGWV
Seijsing et al. In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor
US8618247B2 (en) Peptide, use of the peptide, method for the production of the peptide, solid support having the peptide immobilized thereon, and method for production of the solid support
Rispens et al. Fc–Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer
JP7853912B2 (ja) 免疫グロブリン検出と関連する療法
Falkenburg et al. Anti-hinge antibodies recognize IgG subclass–and protease-restricted neoepitopes
Kaul et al. Dissection of C1q capability of interacting with IgG: time-dependent formation of a tight and only partly reversible association
Wessig et al. Natural antibodies and CRP drive anaphylatoxin production by urate crystals
CN114702580B (zh) 特异性结合人血清白蛋白单克隆抗体及其应用
Song et al. Protective effect of scFv‐DAF fusion protein on the complement attack to acetylcholine receptor: A possible option for treatment of myasthenia gravis
BR122024021835A2 (pt) Composição para ligação a um anticorpo anti-cd47, kit para investigação de biomonitoramento e ensaios de diagnóstico, métodos para: neutralização ou bloqueio da ligação de um anticorpo anti-cd47, seleção de uma unidade adequada de hemácias e remoção de anti-cd47 no plasma, soro e/ou sangue humano, e proteína de fusão.
BR122024021803A2 (pt) Marcador de oligomerização para uma proteína de fusão recombinante, e proteína de fusão
Gnann et al. Resolving the Interference of Anti‐CD38 Antibodies on Blood Compatibility Assays Using CD38 “Baitbodies” Approach

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200811

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210203

R150 Certificate of patent or registration of utility model

Ref document number: 6833851

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250